Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02984124 · ClinicalTrials.gov registry record · Phase 2
Communication During Hospitalization About Resuscitation Trial
A Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD, sponsored by University of Vermont.
- Active
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 4
- Study locations
NCT02984124: Active Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD, sponsored by University of Vermont.
NCT02984124 is a Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD that is active but no longer recruiting, run by University of Vermont. The registered enrollment target is 182 participants, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (78% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02984124, a Phase 2 study of End Stage Renal Disease and Severe Life-limiting COPD, is active but no longer recruiting, sponsored by University of Vermont.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 4
- Study locations
Study Summary
This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.
Primary Outcome
Patient-Assessed Quality of Communication about CPR
Conditions Studied
Interventions
- BEHAVIORAL Informed Assent Discussion
- BEHAVIORAL Usual Care with Attention Control
Study Locations (4)
North Carolina
- University of North Carolina - Chapel Hill
South Carolina
- Medical University of South Carolina - Charleston
Vermont
- University of Vermont - Burlington
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What the registry record for NCT02984124 still lists
NCT02984124 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 831-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (78% lower).
The record links to 6 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Informed Assent Discussion is the first listed.
NCT02984124 reports a single indexed study location in North Carolina, South Carolina, Vermont.
Frequently Asked Questions
What is clinical trial NCT02984124 about?
NCT02984124 is a clinical study titled "Communication During Hospitalization About Resuscitation Trial". This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.
What is the current status of trial NCT02984124?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2016-12. Estimated completion is 2025-12.
What conditions does trial NCT02984124 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy.
What interventions are being tested in trial NCT02984124?
The interventions under investigation include: Informed Assent Discussion (BEHAVIORAL), Usual Care with Attention Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT02984124?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02984124 being conducted?
This trial has 4 study locations across North Carolina, South Carolina, Vermont, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02984124's enrollment target sits among peer trials
182 22nd of 86 higher than 65 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
-
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia